Enhanced Radiological Detection of a Corticotroph Adenoma Following Treatment With Osilodrostat.

Zin Htut, Lisa Yang, James MacFarlane, Daniel Gillett, Mark Gurnell, Florian Wernig

Abstract readCase Reports

In one paragraph

Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Functional pituitary adenoma imaging.Reviews in endocrine & metabolic disorders · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zin HtutDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.

Lisa YangDepartment of Endocrinology, Imperial College Healthcare NHS Trust, London, UK.

James MacFarlaneDepartment of Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID https://orcid.org/0000-0001-6937-2775

Daniel GillettCambridge Endocrine Molecular Imaging Group, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Mark GurnellDepartment of Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID https://orcid.org/0000-0001-5745-6832

Florian WernigDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.ORCID https://orcid.org/0000-0001-5914-9318

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In approximately 30% of patients with Cushing disease, pituitary magnetic resonance imaging (MRI) does not reliably identify a corticotroph adenoma. Importantly, surgical remission rates are >2.5 fold higher for microadenomas that are radiologically visible on preoperative imaging when compared with "MRI-negative" cases. We describe a 42-year-old woman with Cushing disease, in whom MRI findings at presentation were equivocal with no clear adenoma visualized. She was initially treated with metyrapone, which resulted in partial biochemical control of hypercortisolism. After switching to osilodrostat, there was a marked improvement in her symptoms and rapid normalization of cortisol levels. Following 3 months of eucortisolemia, [11C]methionine positron emission tomography (MET-PET) coregistered with volumetric MRI (MET-PET/MR

Indexed as

[11C]methionine PETcorticotroph adenomaCushing diseaseosilodrostat

Identifiers

PMID41064661

DOI10.1210/jcemcr/luaf200

PMCPMC12501498

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.